BEAM
Beam Therapeutics Inc.
$34.79
+1.31 (+3.91%)
At close · Jul 2
Market Cap
$3.58B
Shares
102,879,214
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$34.79
Open$33.82
Day$33.64–35.74
52W$15.60–36.88
Avg vol 30d2.2M
Short int28.3M · 27.5% float · 14.2d
Short vol63%
Last earningsMay 7, 2026
DataFeb 2020–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Strong Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+26% above
+
Price vs 50-day avg
+12% above
◦
RSI (14)
59 · neutral
+
MACD trend
positive
+
52-week position
90% · near high
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $31 › 200d $28 — 50d above 200d
−
Institutional flow
2 of 253 funds reported for Jun 30 · net -8 sh shares
−
Insider flow
Net -$10.0M over 90 days · 100% sells
−
Short interest
27.52% of float · ▲ +31.9% MoM · 14.2 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
253 holders — near 3-yr high, broad support
Fundamentals
Strong
+
Revenue growth
+33% Y/Y
+
EPS growth
+82% Y/Y
−
Free cash flow
$-360.0M
+
Balance sheet
net cash $294.9M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+26% above
Bullish
Price vs 50-day avg
+12% above
Bullish
RSI (14)
59 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
90% · near high
Bullish
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $31 › 200d $28 — 50d above 200d
Institutional flow
Distributing
2 of 253 funds reported for Jun 30 · net -8 sh shares
Insider flow
Distributing
Net -$10.0M over 90 days · 100% sells
Short interest
Rising
27.52% of float · ▲ +31.9% MoM · 14.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
253 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $16
Now $35 · 90%
52-wk high $37
vs 200-day avg +26%
vs 50-day avg +12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and marketable securities | 1.2B | Q1 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BEAM
this stock
Beam Therapeutics Inc.
|
$3.58B | +25.5% | +33.3% | — | 27.5% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BEAM | +2.5% | +17.7% | +24.3% | +1.4% | +25.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +1.1% | +19.0% | +16.2% | +1.6% | +16.3% |